You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTiagabine
Accession NumberDB00906  (APRD00344)
TypeSmall Molecule
GroupsApproved
DescriptionTiagabine is an anti-convulsive medication. It is also used in the treatment for panic disorder as are a few other anticonvulsants. Though the exact mechanism by which tiagabine exerts its effect on the human body is unknown, it does appear to operate as a selective GABA reuptake inhibitor.
Structure
Thumb
Synonyms
Gabitril
Tiagabina
Tiagabinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Gabitriltablet, film coated16 mg/1oralCephalon, Incorporated1997-11-03Not applicableUs
Gabitriltablet12 mg/1oralSTAT Rx USA LLC1997-11-03Not applicableUs
Gabitriltablet, film coated2 mg/1oralCephalon, Incorporated1997-11-03Not applicableUs
Gabitriltablet4 mg/1oralCarilion Materials Management1997-11-03Not applicableUs
Gabitriltablet4 mg/1oralLake Erie Medical & Surgial Supply DBA Quality Care Products LLC2011-11-15Not applicableUs
Gabitriltablet, film coated4 mg/1oralCephalon, Incorporated1997-11-03Not applicableUs
Gabitriltablet, film coated12 mg/1oralCephalon, Incorporated1997-11-03Not applicableUs
Tiagabine Hydrochloridetablet, film coated2 mg/1oralCima Labs Inc.2012-12-21Not applicableUs
Tiagabine Hydrochloridetablet, film coated4 mg/1oralCima Labs Inc.2012-12-21Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Tiagabine Hydrochloridetablet, film coated2 mg/1oralSun Pharmaceutical Industries Limited2011-11-04Not applicableUs
Tiagabine Hydrochloridetablet, film coated4 mg/1oralSun Pharmaceutical Industries Limited2011-11-04Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Tiagabine hydrochloride
ThumbNot applicableDBSALT001255
Categories
UNIIZ80I64HMNP
CAS number115103-54-3
WeightAverage: 375.548
Monoisotopic: 375.132670429
Chemical FormulaC20H25NO2S2
InChI KeyInChIKey=PBJUNZJWGZTSKL-MRXNPFEDSA-N
InChI
InChI=1S/C20H25NO2S2/c1-14-7-11-24-18(14)17(19-15(2)8-12-25-19)6-4-10-21-9-3-5-16(13-21)20(22)23/h6-8,11-12,16H,3-5,9-10,13H2,1-2H3,(H,22,23)/t16-/m1/s1
IUPAC Name
(3R)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-en-1-yl]piperidine-3-carboxylic acid
SMILES
CC1=C(SC=C1)C(=CCCN1CCC[[email protected]](C1)C(O)=O)C1=C(C)C=CS1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as piperidinecarboxylic acids. These are compounds containing a piperidine ring which bears a carboxylic acid group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPiperidines
Sub ClassPiperidinecarboxylic acids and derivatives
Direct ParentPiperidinecarboxylic acids
Alternative Parents
Substituents
  • Piperidinecarboxylic acid
  • Heteroaromatic compound
  • Thiophene
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of partial seizures
PharmacodynamicsTiagabine is used primarily as an anticonvulsant for the adjunctive treatment of epilepsy. The precise mechanism by which Tiagabine exerts its antiseizure effect is unknown, although it is believed to be related to its ability to enhance the activity of gamma aminobutyric acid (GABA), the major inhibitory neurotransmitter in the central nervous system. Tiagabine binds to recognition sites associated with the GABA uptake carrier. It is thought that, by this action, Tiagabine blocks GABA uptake into presynaptic neurons, permitting more GABA to be available for receptor binding on the surfaces of post-synaptic cells.
Mechanism of actionThough the exact mechanism by which Tiagabine exerts its effect on the human body is unknown, it does appear to operate as a selective GABA reuptake inhibitor.
Related Articles
AbsorptionTiagabine is nearly completely absorbed (>95%).
Volume of distributionNot Available
Protein binding96%
Metabolism

Tiagabine is likely metabolized primarily by the 3A isoform subfamily of hepatic cytochrome P450.

SubstrateEnzymesProduct
Tiagabine
UnknownDetails
Route of eliminationApproximately 2% of an oral dose of tiagabine is excreted unchanged, with 25% and 63% of the remaining dose excreted into the urine and feces, respectively, primarily as metabolites.
Half life7-9 hours
Clearance
  • 109 mL/min [Healthy subjects]
Toxicitymptoms most often accompanying tiagabine overdose, alone or in combination with other drugs, have included: seizures including status epilepticus in patients with and without underlying seizure disorders, nonconvulsive status epilepticus, coma, ataxia, confusion, somnolence, drowsiness, impaired speech, agitation, lethargy, myoclonus, spike wave stupor, tremors, disorientation, vomiting, hostility, and temporary paralysis. Respiratory depression was seen in a number of patients, including children, in the context of seizures.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9603
Blood Brain Barrier+0.9382
Caco-2 permeable-0.5368
P-glycoprotein substrateSubstrate0.6504
P-glycoprotein inhibitor INon-inhibitor0.6879
P-glycoprotein inhibitor IINon-inhibitor0.9609
Renal organic cation transporterInhibitor0.5083
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.5299
CYP450 1A2 substrateInhibitor0.5784
CYP450 2C9 inhibitorNon-inhibitor0.6727
CYP450 2D6 inhibitorNon-inhibitor0.812
CYP450 2C19 inhibitorNon-inhibitor0.5865
CYP450 3A4 inhibitorNon-inhibitor0.9568
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7011
Ames testNon AMES toxic0.7455
CarcinogenicityNon-carcinogens0.9505
BiodegradationReady biodegradable0.5139
Rat acute toxicity2.5164 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5333
hERG inhibition (predictor II)Non-inhibitor0.8672
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Cephalon inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral12 mg/1
Tabletoral4 mg/1
Tablet, film coatedoral12 mg/1
Tablet, film coatedoral16 mg/1
Tablet, film coatedoral2 mg/1
Tablet, film coatedoral4 mg/1
Prices
Unit descriptionCostUnit
Gabitril 16 mg tablet12.53USD tablet
Gabitril 12 mg tablet6.4USD tablet
Gabitril 2 mg tablet4.89USD tablet
Gabitril 4 mg tablet3.9USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5010090 No1994-09-302011-09-30Us
US5866590 No1996-04-292016-04-29Us
US5958951 No1997-06-102017-06-10Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP2.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0211 mg/mLALOGPS
logP4.98ALOGPS
logP2.6ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)4.14ChemAxon
pKa (Strongest Basic)9.26ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area40.54 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity115.32 m3·mol-1ChemAxon
Polarizability41.7 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Henning Petersen, Peter Nielsen, Michael Cain, Subhash Patel, “Crystalline Tiagabine monohydrate, its preparation and use.” U.S. Patent US5354760, issued April, 1991.

US5354760
General ReferencesNot Available
External Links
ATC CodesN03AG06
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (251 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Tiagabine.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Tiagabine.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Tiagabine.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Tiagabine.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Tiagabine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Tiagabine.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Tiagabine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Tiagabine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tiagabine.
AmiodaroneThe metabolism of Tiagabine can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Tiagabine.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Tiagabine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Tiagabine.
AmoxapineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Tiagabine.
AprepitantThe serum concentration of Tiagabine can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tiagabine.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Tiagabine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Tiagabine.
AtazanavirThe metabolism of Tiagabine can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Tiagabine can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Tiagabine.
AzelastineTiagabine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Tiagabine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Tiagabine.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Tiagabine.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Tiagabine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Tiagabine.
BexaroteneThe serum concentration of Tiagabine can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Tiagabine can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Tiagabine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Tiagabine can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Tiagabine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.
BrimonidineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tiagabine.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Tiagabine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Tiagabine.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tiagabine.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Tiagabine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Tiagabine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tiagabine.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Tiagabine.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Tiagabine.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Tiagabine.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Tiagabine.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tiagabine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tiagabine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Tiagabine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Tiagabine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Tiagabine.
CeritinibThe serum concentration of Tiagabine can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Tiagabine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Tiagabine.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tiagabine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Tiagabine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Tiagabine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tiagabine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tiagabine.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Tiagabine.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tiagabine.
CitalopramThe risk or severity of adverse effects can be increased when Tiagabine is combined with Citalopram.
ClarithromycinThe metabolism of Tiagabine can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Tiagabine can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Tiagabine.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Tiagabine.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Tiagabine.
ClomipramineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Tiagabine is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Tiagabine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tiagabine.
ClotrimazoleThe metabolism of Tiagabine can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Tiagabine.
CobicistatThe metabolism of Tiagabine can be decreased when combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Tiagabine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Tiagabine.
ConivaptanThe serum concentration of Tiagabine can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Tiagabine can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tiagabine.
CyclosporineThe metabolism of Tiagabine can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Tiagabine.
DabrafenibThe serum concentration of Tiagabine can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Tiagabine is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tiagabine.
DapoxetineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Dapoxetine.
DarunavirThe metabolism of Tiagabine can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Tiagabine can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Tiagabine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Tiagabine can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Tiagabine.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Tiagabine.
DesipramineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Tiagabine.
DexamethasoneThe serum concentration of Tiagabine can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tiagabine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tiagabine.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Tiagabine.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tiagabine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Tiagabine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Tiagabine.
DifenoxinThe risk or severity of adverse effects can be increased when Tiagabine is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tiagabine.
DihydroergotamineThe metabolism of Tiagabine can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Tiagabine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tiagabine.
DiltiazemThe metabolism of Tiagabine can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Tiagabine is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tiagabine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tiagabine.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Tiagabine.
DoxepinThe risk or severity of adverse effects can be increased when Tiagabine is combined with Doxepin.
DoxycyclineThe metabolism of Tiagabine can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.
DoxylamineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Tiagabine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.
DronedaroneThe metabolism of Tiagabine can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Tiagabine.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Tiagabine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tiagabine.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Tiagabine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Tiagabine.
EfavirenzThe serum concentration of Tiagabine can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Tiagabine is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Tiagabine.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Tiagabine.
EnzalutamideThe serum concentration of Tiagabine can be decreased when it is combined with Enzalutamide.
ErythromycinThe metabolism of Tiagabine can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Tiagabine is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Tiagabine can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Tiagabine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tiagabine.
EthanolTiagabine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Tiagabine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tiagabine.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tiagabine.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Tiagabine.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tiagabine.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Tiagabine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tiagabine.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Tiagabine.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Tiagabine.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Tiagabine.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Tiagabine.
EtoperidoneThe risk or severity of adverse effects can be increased when Tiagabine is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Tiagabine.
EtravirineThe serum concentration of Tiagabine can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Tiagabine is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Tiagabine.
FenfluramineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tiagabine.
FexofenadineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Tiagabine is combined with Flibanserin.
FluconazoleThe metabolism of Tiagabine can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Tiagabine.
FlunarizineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Tiagabine.
FluoxetineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tiagabine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Tiagabine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tiagabine.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Tiagabine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Tiagabine.
FluvoxamineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Fluvoxamine.
FluvoxamineThe metabolism of Tiagabine can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Tiagabine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Tiagabine can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Tiagabine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Tiagabine.
Fusidic AcidThe serum concentration of Tiagabine can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tiagabine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Tiagabine is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Tiagabine.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Tiagabine.
GuanfacineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Tiagabine.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Tiagabine.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Tiagabine.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Tiagabine.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Tiagabine.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Tiagabine.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Tiagabine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.
HydroxyzineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Hydroxyzine.
IdelalisibThe serum concentration of Tiagabine can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Tiagabine is combined with Iloperidone.
ImatinibThe metabolism of Tiagabine can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Tiagabine.
IndalpineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Indalpine.
IndinavirThe metabolism of Tiagabine can be decreased when combined with Indinavir.
IsavuconazoniumThe metabolism of Tiagabine can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Tiagabine.
IsradipineThe metabolism of Tiagabine can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Tiagabine can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Tiagabine can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Tiagabine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Tiagabine.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Tiagabine.
KetoconazoleThe metabolism of Tiagabine can be decreased when combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tiagabine.
LevetiracetamThe risk or severity of adverse effects can be increased when Tiagabine is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Tiagabine.
LevocabastineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Tiagabine is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tiagabine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Tiagabine is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tiagabine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Tiagabine.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Tiagabine.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Tiagabine.
LopinavirThe metabolism of Tiagabine can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Tiagabine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Tiagabine.
LovastatinThe metabolism of Tiagabine can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Tiagabine.
Lu AA21004The risk or severity of adverse effects can be increased when Tiagabine is combined with Lu AA21004.
LuliconazoleThe serum concentration of Tiagabine can be increased when it is combined with Luliconazole.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tiagabine.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Tiagabine is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Tiagabine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Tiagabine.
MefloquineThe therapeutic efficacy of Tiagabine can be decreased when used in combination with Mefloquine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Tiagabine.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Tiagabine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tiagabine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tiagabine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tiagabine.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Tiagabine.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Tiagabine.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Tiagabine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Tiagabine.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Tiagabine.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Tiagabine.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Tiagabine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Tiagabine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Tiagabine.
MethsuximideThe risk or severity of adverse effects can be increased when Tiagabine is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Tiagabine.
MetyrosineTiagabine may increase the sedative activities of Metyrosine.
MianserinThe therapeutic efficacy of Tiagabine can be decreased when used in combination with Mianserin.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Tiagabine.
MifepristoneThe metabolism of Tiagabine can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Tiagabine is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.
MirtazapineTiagabine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Tiagabine.
MitotaneThe serum concentration of Tiagabine can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Tiagabine can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Tiagabine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Tiagabine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.
NabiloneThe risk or severity of adverse effects can be increased when Tiagabine is combined with Nabilone.
NafcillinThe serum concentration of Tiagabine can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tiagabine.
NefazodoneThe metabolism of Tiagabine can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Tiagabine can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Tiagabine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Tiagabine can be decreased when combined with Nevirapine.
NilotinibThe metabolism of Tiagabine can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tiagabine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Tiagabine.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Tiagabine.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Tiagabine.
OlanzapineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Olanzapine.
OlaparibThe metabolism of Tiagabine can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tiagabine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Tiagabine.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Tiagabine.
OrlistatThe serum concentration of Tiagabine can be decreased when it is combined with Orlistat.
OrphenadrineTiagabine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Tiagabine.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Tiagabine.
OsimertinibThe serum concentration of Tiagabine can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tiagabine.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tiagabine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Tiagabine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tiagabine.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tiagabine.
PalbociclibThe serum concentration of Tiagabine can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tiagabine.
ParaldehydeTiagabine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Tiagabine.
ParoxetineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tiagabine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Tiagabine.
PerampanelThe risk or severity of adverse effects can be increased when Tiagabine is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Tiagabine.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Tiagabine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Tiagabine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Tiagabine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Tiagabine.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Tiagabine.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Tiagabine.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Tiagabine.
PipotiazineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Tiagabine is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Tiagabine is combined with Pomalidomide.
PosaconazoleThe metabolism of Tiagabine can be decreased when combined with Posaconazole.
PramipexoleTiagabine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Tiagabine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Tiagabine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Tiagabine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Tiagabine.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Tiagabine.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Tiagabine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tiagabine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Tiagabine.
PromethazineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Tiagabine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Tiagabine.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Tiagabine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Tiagabine.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Tiagabine.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Tiagabine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tiagabine.
RamelteonThe risk or severity of adverse effects can be increased when Tiagabine is combined with Ramelteon.
RanolazineThe metabolism of Tiagabine can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tiagabine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tiagabine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Tiagabine.
RifabutinThe metabolism of Tiagabine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Tiagabine can be increased when combined with Rifampicin.
RifapentineThe metabolism of Tiagabine can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Tiagabine.
RitonavirThe metabolism of Tiagabine can be decreased when combined with Ritonavir.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Tiagabine.
RopiniroleTiagabine may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tiagabine.
RotigotineTiagabine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Tiagabine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Tiagabine.
SaquinavirThe metabolism of Tiagabine can be decreased when combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tiagabine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tiagabine.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Tiagabine.
SertralineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tiagabine.
SildenafilThe metabolism of Tiagabine can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Tiagabine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Tiagabine can be increased when it is combined with Simeprevir.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Tiagabine.
St. John's WortThe serum concentration of Tiagabine can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Tiagabine is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tiagabine.
SulfisoxazoleThe metabolism of Tiagabine can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tiagabine.
SuvorexantThe risk or severity of adverse effects can be increased when Tiagabine is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Tiagabine is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Tiagabine is combined with Tasimelteon.
TelaprevirThe metabolism of Tiagabine can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Tiagabine can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Tiagabine.
TetrabenazineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Tiagabine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Tiagabine.
ThalidomideTiagabine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Tiagabine.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tiagabine.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Tiagabine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Tiagabine.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tiagabine.
TiclopidineThe metabolism of Tiagabine can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Tiagabine.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Tiagabine.
TocilizumabThe serum concentration of Tiagabine can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tiagabine.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Tiagabine.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Tiagabine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Tiagabine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tiagabine.
TrazodoneThe risk or severity of adverse effects can be increased when Tiagabine is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Tiagabine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tiagabine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tiagabine.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Tiagabine.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Tiagabine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Tiagabine.
VenlafaxineThe metabolism of Tiagabine can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Tiagabine can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Tiagabine is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Tiagabine is combined with Vilazodone.
VoriconazoleThe metabolism of Tiagabine can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Tiagabine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Tiagabine.
ZiconotideThe risk or severity of adverse effects can be increased when Tiagabine is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Zimelidine.
ZiprasidoneThe metabolism of Tiagabine can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Tiagabine is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Tiagabine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Tiagabine.
ZonisamideThe risk or severity of adverse effects can be increased when Tiagabine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Tiagabine.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Tiagabine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tiagabine.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Neurotransmitter:sodium symporter activity
Specific Function:
Terminates the action of GABA by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A1
Uniprot ID:
P30531
Molecular Weight:
67073.0 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Pollack MH, Roy-Byrne PP, Van Ameringen M, Snyder H, Brown C, Ondrasik J, Rickels K: The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. J Clin Psychiatry. 2005 Nov;66(11):1401-8. [PubMed:16420077 ]
  3. Sheehan DV, Sheehan KH, Raj BA, Janavs J: An open-label study of tiagabine in panic disorder. Psychopharmacol Bull. 2007;40(3):32-40. [PubMed:18007567 ]
  4. Foster AC, Kemp JA: Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17. Epub 2005 Dec 22. [PubMed:16377242 ]
  5. Sunol C, Babot Z, Cristofol R, Sonnewald U, Waagepetersen HS, Schousboe A: A possible role of the non-GAT1 GABA transporters in transfer of GABA from GABAergic to glutamatergic neurons in mouse cerebellar neuronal cultures. Neurochem Res. 2010 Sep;35(9):1384-90. doi: 10.1007/s11064-010-0196-1. Epub 2010 May 30. [PubMed:20512624 ]
  6. Henjum S, Hassel B: High-affinity GABA uptake and GABA-metabolizing enzymes in pig forebrain white matter: a quantitative study. Neurochem Int. 2007 Jan;50(2):365-70. Epub 2006 Oct 27. [PubMed:17069932 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 30, 2016 02:25